Taiho Pharmaceutical Company Limited

Hiroki Irie

Takeshi Sagara

Kazutaka Miyadera

Yuichi Kawai

Kei Oguchi

Yayoi Fujioka

Provided is an anti-tumor agent for the treatment of a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor. More specifically provided is a therapeutic agent for a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor, which contains a pyrazolo[3,4-d]pyrimidine compound or a salt thereof as an active ingredient.

Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient

To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z, Z, Z, Z, W, n, R, R, and Rhave meanings as defined in the present specification, or a salt thereof and other antitumor agent(s) for combined administration.

Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound

To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 inhibitory effect. The present invention provides a compound of formula (I) wherein X, Y, Z, Z, Z, Z, W, n, R, R, and Rhave meanings as defined in the present specification, or a salt thereof. 

Growing community of inventors

Tsukuba, Japan

Hiroki Irie